Authors

Latest:

Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.

Jeannette Y. Wick, RPh, MBA, FASCP

Latest:

Learning the Lingo of Biologics and Biosimilars Is Critical

The number of FDA-approved biologics has exploded, and biosimilars are making their mark.

Wayne Winegarden, PhD

Wayne Winegarden is a senior fellow and director center for medical economics and innovation at Pacific Research Institute. He received his PhD in economics from George Mason University.

Latest:

Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?

If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.

Elena Wolff-Holz, MD

Global Head Clinical Development, Biocon Biologics

Latest:

The Global Biosimilar Development and Approval of Yesintek With Elena Wolff-Holz, MD

Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics, discussed the approval of BMAb-1200, a biosimilar to reference ustekinumab for psoriasis, highlighting comparable efficacy and safety data while noting challenges in global patient recruitment and regulatory navigation.

Rosalind Wong, PharmD Candidate

Rosalind Wong is a PharmD candidates at the Daniel K. Inouye College of Pharmacy at the University of Hawai’i at Hilo.

Latest:

Common Patient Questions About Insulin Biosimilars Pertain to Classification

Nuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.

Gillian Woollett, MA, DPhil

Gillian Woollett, MA, DPhil, is the the vice president and head of regulatory strategy and policy at Samsung Bioepis. Prior to her work at Samsung Bioepis, she served as Avalere Health's senior vice president for over 10 years.

Latest:

Confusion Persists Around the Interchangeability Designation for Biosimilars

The legal and common uses of “interchangeability” continue to be conflated.

Prateek Yadav, MPTh, MBA

Prateek Yadav, MPTh, MBA, a manager at

Latest:

The Next Frontier: Oncology Biosimilars in 2025 and Beyond

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.

Robert Zutaut, RPh

Robert Zutaut, RPh, a clinical specialist from McKesson Provider Solutions

Latest:

Pharmacy Can Help Drive Adoption of Rheumatoid Arthritis Biosimilars

Pharmacists will have the opportunity to use their knowledge of biosimilars to reinforce their benefits, safety, and efficacy.

Mark Campbell, PharmD

Mark Campbell, PharmD, is the chief pharmacy officer at RxBenefits.

Latest:

A Promise Unfulfilled: The State of Biosimilars

For biosimilars to overcome these entrenched market dynamics, they must not only compete on price but actively work to build a network of support among providers and patients.

Lisa Lasita, PharmD, MBA

Lisa Lasita, PharmD, MBA

Latest:

Integrating Biosimilars Into Retina and Neurology Practices Requires Careful Planning

Successfully integrating biosimilars into practices requires careful planning and execution, as they impact virtually all aspects of a practice.

Advertisement

Advertisement